Part II: Chemotherapy for epithelial ovarian cancer-treatment of rcurrent disease
- 1 September 2002
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (9), 537-545
- https://doi.org/10.1016/s1470-2045(02)00847-1
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- ZD0473 phase II monotherapy trial in second-line ovarian cancerEuropean Journal Of Cancer, 2001
- Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian CarcinomaGynecologic Oncology, 2001
- Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian CancerGynecologic Oncology, 2000
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- Hexamethylmelamine as a Single Second-Line Agent in Ovarian Cancer: Follow-up Report and Review of the LiteratureGynecologic Oncology, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary ReportGynecologic Oncology, 1996
- Phase II trial of epirubicin at standard dose in relapsed ovarian cancerEuropean Journal Of Cancer, 1996
- Epirubicin for pretreated advanced ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990